Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.

Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis. World J Gastroenterol. 2019 Jun 21;25(23):2935-2946 Authors: Gelman S, Salteniene V, Pranculis A, Skieceviciene J, Zykus R, Petrauskas D, Kupcinskas L, Canbay A, Link A, Kupcinskas J Abstract BACKGROUND: Clinically significant portal hypertension (CSPH) and severe portal hypertension (SPH) increase the risk for decompensation and life-threatening complications in liver cirrhosis. Pathologic angiogenesis might contribute to the formation of these conditions. Placental growth factor (PlGF) and Nogo-A protein are biomarkers of pathological angiogenesis, but data on their role in liver cirrhosis and portal hypertension is scarce. AIM: To determine plasma levels of PlGF and Nogo-A in patients with liver cirrhosis, CSPH, SPH and potential to predict portal hypertension. METHODS: A cohort of 122 patients with hepatitis C virus and/or alcohol-induced liver cirrhosis with characterized hepatic venous pressure gradient (HVPG) were included in the study. Demographic data, medical history, Child-Turcotte-Pugh and Model of End Stage liver disease score, clinical chemistry, liver stiffness values were recorded on the day of the procedure prior HVPG measurement. The degree of portal hypertension was determined by the invasive HVPG measurement. Nogo-A and PlGF plasma levels were evaluated using enzyme linked immunosorbent assay. The contro...
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Tags: World J Gastroenterol Source Type: research

Related Links:

Conclusion Massive SI and immune cell paralysis associated with ACLF represent the extreme severity of CAID in response to an infectious or sterile challenge. The severe immune disturbance plays a pivotal role in the pathogenesis of the distinctive features of ACLF: organ failure and bacterial infection susceptibility. Excessive SI in ACLF results from the massive activation and dysfunction of an innate immune system challenged by increased PAMPs and DAMPs. SI leads to cell and tissue immunopathology contributing to hepatic and extrahepatic organ failure. Concomitantly, the course of ACLF is associated with a disproportio...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This study is registered with ClinicalTrials.gov, number NCT01953458.FindingsBetween Aug 6, 2012, and Dec 31, 2015, 10 166 patients were eligible for the study. 9895 (97%) patients had available follow-up information and were included in analyses. Median follow-up was 33·4 months (IQR 24·0–40·7). Treatment with direct-acting antivirals was initiated during follow-up in 7344 patients, and 2551 patients remained untreated at the final follow-up visit. During follow-up, 218 patients died (129 treated, 89 untreated), 258 reported hepatocellular carcinoma (187 treated, 71 untreated), and 106 had dec...
Source: The Lancet - Category: General Medicine Source Type: research
AbstractAimsTo investigate the relationship between HbA1c and glucose in people with co ‐existing liver disease and diabetes awaiting transplant, and in those with diabetes but no liver disease.MethodsHbA1c and random plasma glucose data were collected for 125 people with diabetes without liver disease and for 29 people awaiting liver transplant with diabetes and cirrhosis. The median (interquartile range) Model for End Stage Liver Disease score for the study cohort was calculated as 12 (9 –17; normal
Source: Diabetic Medicine - Category: Endocrinology Authors: Tags: Research Article Source Type: research
AbstractPortal hypertension (PHT) is a frequent and severe complication of cirrhosis. PHT may lead to the development of various complications with high mortality. Liver transplantation is the gold standard as a surgical curative treatment for end-stage liver disease. Theoretically, etiological treatment focusing on the pathophysiology of the underlying disease should be the objective of the nonsurgical management of cirrhotic PHT. Chronic viral hepatitis is the major etiology of cirrhosis and PHT. In cirrhotic patients with chronic hepatitis B virus infection, antiviral therapies can suppress viral replication, ameliorate...
Source: Hepatology International - Category: Infectious Diseases Source Type: research
ABSTRACT Patients with compensated advanced chronic liver disease (cACLD) can safely avoid screening endoscopy with a platelet count>150x109 cells/L and liver stiffness measurement (LSM)
Source: Hepatology - Category: Internal Medicine Authors: Tags: Liver Failure, Cirrhosis and Portal Hypertension Source Type: research
Conclusion: 2D‐SWE has good to excellent performance for the non‐invasive staging of liver fibrosis in patients with hepatitis B. Further prospective studies are needed for head to head comparison between 2D SWE and other imaging modalities to establish disease‐specific appropriate cut‐points for assessment of fibrosis stage. This article is protected by copyright. All rights reserved.
Source: Hepatology - Category: Internal Medicine Authors: Tags: Liver Failure, Cirrhosis and Portal Hypertension Source Type: research
Liver fibrosis is a common pathway in multiple liver diseases, including viral (hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV)-HCV co-infection), autoimmune, hereditary, metabolic and toxin-mediated liver disease. These diseases can lead to hepatocellular dysfunction, distortion of liver architecture, portal hypertension and finally liver cirrhosis. Approximately 20 to 30% of patients with chronic liver disease develop cirrhosis 1. In addition, the incidence of cirrhosis is increasing due to other causes like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steato-hepatitis ...
Source: Seminars in Roentgenology - Category: Radiology Authors: Source Type: research
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 78-year-old woman with a past medical history of hepatitis C virus (HCV) presented on routine examinati...
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Oncology Grand Rounds Source Type: research
In conclusion, liver‐derived HRG, similar to alarmins, appears to be an endogenous molecular factor promoting the polarization of hepatic macrophages towards the M1 phenotype, thereby endorsing chronic liver injury and fibrosis progression, but limiting angiogenesis. Controlling tissue levels of HRG or PGF might therefore be a promising strategy in chronic inflammatory liver diseases. This article is protected by copyright. All rights reserved.
Source: Hepatology - Category: Internal Medicine Authors: Tags: Liver Failure, Cirrhosis and Portal Hypertension Source Type: research
Authors: Trovato FM, Tognarelli JM, Crossey MM, Catalano D, Taylor-Robinson SD, Trovato GM Abstract Chronic liver disease has become a global health problem as a result of the increasing incidence of viral hepatitis, obesity and alcohol misuse. Over the past three decades, in the United Kingdom alone, deaths from chronic liver disease have increased both in men and in women. Currently, 2.5% of deaths worldwide are attributed to liver disease and projected figures suggest a doubling in hospitalisation and associated mortality by 2020. Chronic liver diseases vary for clinical manifestations and natural history, with ...
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
More News: Alcoholism | Chemistry | Children | Cirrhosis | Gastroenterology | Hepatitis | Hepatitis C | Hypertension | Liver | Liver Disease | Study | Urology & Nephrology